Myopic Choroidal Neovascular Membrane (Myopic CNVM)

Myopic choroidal neovascular membrane (myopic CNVM) is a condition where abnormal blood vessels grow beneath the retina in individuals with high myopia, also known as nearsightedness. These vessels can leak fluid or blood, leading to blurred or distorted vision, and potentially causing significant visual impairment if left untreated. 

Myopic choroidal neovascular membrane (myopic CNVM) is a small patch of abnormal new blood vessels that grows under or just above the light-sensing layer of the eye (the retina) in people with short-sightedness (myopia). These fragile vessels don’t belong there. They leak blood and fluid, scar the central retina (the macula), and blur or distort central vision. Without treatment, vision can worsen and a dark or gray spot may appear right where you try to read or recognize faces. In pathologic (degenerative) myopia, breaks in tissue (called lacquer cracks), thinning of the choroid, and mechanical stretch set the stage for this growth. The process is driven by signals such as VEGF (vascular endothelial growth factor) that tell new vessels to sprout to compensate for low oxygen. AAO JournalPMC

• Myopic CNVM is one of the most sight-threatening complications of high/pathologic myopia; without treatment, the long-term outlook used to be poor. Modern care improves this greatly. PubMed+1

• It usually forms in working-age adults with myopia and can be small with little fluid, which means it can be hard to spot without imaging like OCT or OCT-angiography (OCT-A). AAOPMC

• Risk rises with more severe myopia and “plus” lesions such as lacquer cracks and patchy atrophy. PMCReview of Ophthalmology

A myopic choroidal neovascular membrane (myopic CNVM) is a patch of abnormal, fragile new blood vessels that grows in the back of the eye under or within the retina in people with high (pathologic) myopia.
Because the eyeball is long and the tissues in the back of the eye are stretched and thin, tiny cracks can form in a support layer under the retina (Bruch’s membrane). The body responds by releasing growth signals (especially VEGF—vascular endothelial growth factor), which tell new blood vessels to grow. These new vessels are weak and leaky. They ooze fluid and bleed, which blurs central vision, causes wavy lines, and can leave permanent scars if not treated quickly.

---

Pathophysiology

When an eye becomes very long from front to back (axial elongation), tissues in the back of the eye stretch and thin:

• The choroid (the layer that feeds the retina) gets thin and its blood flow weakens.

• The retinal pigment epithelium (RPE) and Bruch’s membrane can crack (lacquer cracks).

• These changes make the central retina oxygen-hungry and leaky to growth signals (especially VEGF).

• New, weak choroidal vessels push through the cracks toward the retina to “help,” but they bleed and scar, damaging central vision.

In myopic CNVM, the neovascular growth is commonly a Type 2 CNV (lying above the RPE, under the retina), it is often small (< ~1 mm), and prominent sub-RPE fluid is uncommon—a pattern that can trick the examiner unless imaging is done carefully. AAOAAO Journal

Among people with pathologic myopia, about 5–11% develop myopic CNVM at some point; in those who already have it in one eye, the other eye can also be affected in a substantial minority over time. Untreated, long-term central vision loss was historically very common, which is why timely detection matters so much. AjoPMCPubMed

---

Types

Think of “types” as ways doctors describe the CNVM so they can talk clearly about risk and treatment.

1. By activity

   • Active (leaky): vessels are growing/leaking; vision is changing; imaging shows activity.

   • Inactive (quiescent/scarred): growth has stopped; a flat scar (Fuchs spot) may remain; vision can be stable but often reduced.

2. By layer

   • Type 2 (subretinal) CNV: above the RPE, typical in myopic CNVM; easier to see on angiography.

   • Type 1 (sub-RPE) CNV: below the RPE (less common in myopia).

3. By location relative to the fovea (the sharpest seeing point)

   • Subfoveal (right under the center),

   • Juxtafoveal (near the center),

   • Extrafoveal (away from the center).
     This matters because subfoveal lesions threaten reading vision the most.

4. By imaging appearance

   • “Classic” on fluorescein angiography (well-defined early hyperfluorescence with late leak).

   • “Occult/poorly defined” (less crisp borders or masked by hemorrhage).
     OCT-A may show an interlacing vascular network with a feeder vessel; imaging patterns help judge activity. Lippincott Journals+1

5. By size

   • Often small (frequently < 1,000 μm), which is why careful imaging is essential. AAO

---

Causes and contributors

Strictly speaking, most of these are risk factors and mechanisms rather than single “causes,” but each pushes the eye toward CNVM. Explained simply:

1. High or pathologic myopia (the eye is very long) → more stretch, more tissue stress. PubMed

2. Lacquer cracks (tiny breaks in Bruch’s membrane/RPE) → an open door for vessels to grow up from the choroid. PMCReview of Ophthalmology

3. Patchy/diffuse chorioretinal atrophy → weak, thin support tissue; easy for vessels to invade. PMC

4. Choroidal thinning → lower blood reserve and oxygen; retina releases more VEGF. Review of Ophthalmology

5. Impaired choroidal circulation (poor flow) → chronic low oxygen; growth signals rise. Review of Ophthalmology

6. Posterior staphyloma (outpouching of the back of the eye) → extra mechanical stretch at the macula. ScienceDirect

7. VEGF up-regulation (the eye’s “grow vessels” signal) → drives abnormal vessel sprouting. PubMed

8. Micro-trauma from normal eye movements in a stretched eye → cumulative tiny damage at the macula (conceptual mechanism supported by stretch-related literature). PMC

9. Age-related weakening of Bruch’s membrane in already thinned myopic eyes → easier to crack. PMC

10. Pre-existing CNVM in the fellow eye → the other eye is at higher risk over time. PMC

11. Fuchs spot history (old macular scar) → indicates prior activity and a fragile macula. PMC

12. Recent small macular hemorrhage in a highly myopic eye → often the first sign that a CNV is forming. Lippincott Journals

13. Thin sclera with perforating vessels seen on modern OCT → a structural setup for neovascular growth. Frontiers

14. Diffuse myopic maculopathy (“plus” lesions) overall → known to raise CNVM risk. PMC

15. Axial length increase over time → the longer the eye, the greater the mechanical stress. PMC

16. Inflammation episodes superimposed on myopic degeneration → can tip the balance toward CNV in susceptible tissue (rule-out is part of the workup). MDPI

17. Genetic susceptibility (general CNV biology: complement and angiogenesis pathways) → not diagnostic alone but may raise risk. MDPI

18. Poor contrast perfusion at the choriocapillaris on OCT-A → a marker of an ischemic environment favoring CNV. PMC

19. Prior laser scars near the macula (rare today) → iatrogenic breaks that can seed CNV. Lippincott Journals

20. Even non-high myopia (less common) → can still develop CNVM, so don’t ignore symptoms just because the glasses prescription isn’t extreme. AAO

---

Symptoms

Each symptom below is written in simple terms and linked to what’s happening inside the eye:

1. Blurred central vision — words or faces lose sharpness because leakage and swelling disrupt the fovea.

2. Distorted lines (metamorphopsia) — straight lines bend or wave; the new vessels and swelling “warp” the retinal grid.

3. A gray, dark, or empty spot in the center (central scotoma) — especially if bleeding blocks the photoreceptors.

4. Colors look washed out — damaged macular cones lower color intensity.

5. Small things look smaller (micropsia) — the stretched, swollen retina mis-scales the image.

6. Reading gets slow and tiring — central fixation is unstable; letters jumble.

7. Faces are hard to recognize — the fine-detail area is exactly where CNVM hits.

8. Worse vision in dim light — impaired macular function reduces contrast sensitivity.

9. Trouble seeing fine contrast (gray-on-gray) — leakage and scarring degrade contrast.

10. Sudden change in one eye while the other stays normal — myopic CNVM often starts in a single eye.

11. Amsler grid looks broken — a classic home clue; boxes look warped or missing.

12. Mild central ache or discomfort with reading — eye strain from forcing clarity.

13. Bright-light recovery is slow — photoreceptors over a leaky lesion reset sluggishly.

14. Occasional small central floater or smudge — tiny bleeds or exudates shift with movement.

15. Anxiety from “good-eye dependence” — everyday tasks feel risky when the reading eye falters.

(Note: acute pain, flashes, or a shower of floaters suggest other problems too; urgent assessment is always wise.)

---

Diagnostic tests

Doctors choose tests to confirm the diagnosis, judge activity, and plan treatment. Below they’re grouped the way a clinic visit unfolds. You won’t need all of them; the mix depends on your eye.

A) Physical exam and simple office assessments

1. Detailed history — sudden central blur/distortion in a myopic adult raises strong suspicion for CNVM.

2. Distance visual acuity (Snellen or ETDRS) — measures how sharp the center vision is today vs. prior visits.

3. Near vision (reading charts such as Jaeger or MNREAD) — captures real-world reading loss from macular damage.

4. Pupil check and brightness comparison — usually normal (no strong RAPD) unless disease is advanced.

5. Confrontation visual fields — may reveal a small central blind area (scotoma).

6. Slit-lamp biomicroscopy with dilated fundus exam — the doctor looks for tiny subretinal hemorrhage, a green-gray CNV patch, lacquer cracks, and myopic maculopathy changes.

B) Manual/functional tests (bedside tools the patient “does”)

7. Amsler grid — at home or in clinic, you stare at a dot; wavy or missing boxes suggest macular trouble (classic for CNVM).

8. Pinhole test — filters out refractive blur; if vision stays poor with pinhole, the problem is retinal, not just glasses.

9. Color vision plates (Ishihara or similar) — macular dysfunction can reduce color discrimination.

10. Contrast sensitivity (e.g., Pelli–Robson) — detects subtle macular performance loss even when acuity still looks “okay.”

11. Photostress recovery — after bright light, delayed clarity suggests macular disease.

12. Reading speed testing (MNREAD) — quantifies the practical impact on reading.

13. Preferential hyperacuity perimetry — detects tiny distortions; helpful in macular disease surveillance.

14. Microperimetry — maps sensitivity point-by-point over the lesion to monitor function during treatment.

C) Lab and pathological tests (to rule out mimics when the story is atypical)

These aren’t routine in classic myopic CNVM but help when inflammation or infection is suspected:

15. Syphilis serology (RPR/TP-PA) — rules out inflammatory CNV from syphilis.

16. TB testing (Quantiferon-TB Gold or T-Spot) — screens for tubercular choroiditis-related CNV.

17. Toxoplasma IgG/IgM — excludes toxoplasma scars with secondary CNV.

18. Inflammatory markers (ESR/CRP, ANA if autoimmune concern) — look for an inflammatory driver.

19. General metabolic labs (as guided by history) — rare systemic contributors can be uncovered.

D) Electrodiagnostic tests (to check global retinal function)

20. Full-field ERG — shows overall retinal health; usually near-normal in isolated myopic CNVM, useful if vision loss is out of proportion to the lesion.

21. Multifocal ERG (mfERG) — focuses on macular function; depressed responses over the CNVM.

22. Visual evoked potentials (VEP) — assesses the visual pathway when the picture is mixed (rarely needed in straightforward CNVM).

23. Electro-oculogram (EOG) — evaluates RPE function if diffuse disease is suspected.

E) Imaging tests (the heart of diagnosis and follow-up)

24. Optical coherence tomography (OCT) — a cross-section “ultrasound-like” scan using light. In myopic CNVM it often shows a shallow, small subretinal complex, sometimes with subretinal fluid, and little to no sub-RPE fluid—a helpful clue that differs from many AMD lesions. AAO

25. OCT angiography (OCT-A) — maps blood flow without dye. It can directly show the CNV network (a tangle or interlacing loops), help judge activity, and is very useful alongside OCT. Systematic reviews report good diagnostic accuracy in suspected myopic CNVM. PMCLippincott Journals

26. Fluorescein angiography (FA/FFA) — a dye test that shows early bright spots with late leakage in “classic” lesions; hemorrhage can sometimes hide details. Lippincott Journals

27. Indocyanine green angiography (ICGA) — penetrates blood better than fluorescein, so it can reveal the CNV when FA is obscured by blood; it also maps the choroid more clearly. Lippincott Journals

28. Color fundus photography (and widefield imaging) — documents baseline and change in hemorrhage, scars, and atrophy.

29. Fundus autofluorescence — shows RPE stress and atrophy around the lesion; helpful for long-term monitoring.

30. Axial length biometry — measures how long the eye is; longer eyes correlate with myopic maculopathy risk. PMC

31. B-scan ocular ultrasound — useful when blood or media haze blocks the view; also shows posterior staphyloma. ScienceDirect

Non-Pharmacological Treatments

These do not replace medical treatment for active CNVM. They protect and support your vision alongside medical care.

1. Urgent presentation & education: Learn the warning signs (sudden distortion, central smudge). Purpose: early treatment saves vision. Mechanism: cuts leak/scar time.

2. Home Amsler grid monitoring: Check each eye daily. Purpose: catch re-activation quickly. Mechanism: detects new distortion.

3. Scheduled follow-ups with OCT: Keep all appointments. Purpose: guide if another injection is needed. Mechanism: imaging shows fluid before vision drops.

4. Low-vision rehabilitation: Training plus magnifiers, electronic readers. Purpose: maximize remaining vision. Mechanism: enlarges text, improves contrast.

5. Task lighting & high-contrast setup: Brighter, focused light; dark-on-light text. Purpose: reduce strain. Mechanism: boosts contrast sensitivity.

6. Screen ergonomics: Larger fonts, high DPI screens, proper distance. Purpose: easier reading. Mechanism: reduces demand on damaged macula.

7. Smoking cessation: Purpose: protect retina. Mechanism: improves micro-blood flow and lowers oxidative stress.

8. Blood pressure/sugar/lipids control: Purpose: better vessel health. Mechanism: less vascular stress on fragile CNV.

9. UV/visible-light protection: Sunglasses + brimmed hat. Purpose: protect thin retina/RPE. Mechanism: less light-induced oxidative damage.

10. Avoid eye rubbing / heavy Valsalva: Purpose: lessen bleed risk. Mechanism: prevents sudden pressure spikes on fragile vessels.

11. Post-injection care: No eye makeup/swimming for a day; report pain or drop in vision. Purpose: prevent infection. Mechanism: reduces bacterial entry.

12. Temporary activity modification: Pause high-impact sports after bleeds/injections. Purpose: reduce re-bleed. Mechanism: minimizes jarring forces.

13. Dry-eye management: Artificial tears, breaks. Purpose: clearer surface optics. Mechanism: sharper image reaching macula.

14. Dietary pattern rich in greens & fish: Purpose: retinal support. Mechanism: antioxidants/omega-3s nourish photoreceptors (see supplements below).

15. Psychological support: Counseling/peer groups. Purpose: reduce anxiety/depression tied to vision changes. Mechanism: coping skills improve adherence.

16. Orientation & mobility training: For significant loss. Purpose: safe moving/travel. Mechanism: techniques for navigation with low vision.

17. Driving assessment: Follow local rules. Purpose: safety. Mechanism: objective check if legal vision standards are met.

18. Home modifications: High-contrast labels, anti-slip strips, large-print clocks. Purpose: independent living. Mechanism: compensates for central loss.

19. Blue-light management on devices: Night mode/filters for comfort. Purpose: reduce glare/strain. Mechanism: subjective comfort; not a cure.

20. Family education: Teach loved ones signs of relapse. Purpose: faster help. Mechanism: early clinic return if changes occur.

---

Drug Treatments

Core message: Anti-VEGF eye injections are the first-line treatment for active myopic CNVM. Most patients need few injections (often 1–3 in the first year), guided by OCT and symptoms. Some agents/approaches below are adjuncts or regional.

1. Ranibizumab (anti-VEGF) – intravitreal

   • Class: Anti-VEGF antibody fragment.

   • Dose & timing: 0.5 mg/0.05 mL, injected into the eye. Often one injection, then PRN (as-needed) monthly follow-up if fluid/vision activity returns.

   • Purpose: Stop leakage, improve/maintain central vision.

   • Mechanism: Neutralizes VEGF, shrinks/leaks less from CNV.

   • Key side effects/risks: Eye infection (endophthalmitis, rare), transient eye pressure rise, small floaters/spots after injection, very rare inflammation or retinal tear/detachment.

2. Aflibercept (anti-VEGF trap) – intravitreal

   • Class: VEGF-A/PlGF “trap” fusion protein.

   • Dose & timing: 2 mg/0.05 mL intravitreal. Often single injection, then PRN based on OCT/vision.

   • Purpose: Same goals as above.

   • Mechanism: Binds VEGF-A and PlGF, starves CNV of growth signals.

   • Side effects: As above for intravitreal anti-VEGF.

3. Bevacizumab (anti-VEGF) – intravitreal, off-label

   • Class: Full-length anti-VEGF antibody.

   • Dose & timing: 1.25 mg/0.05 mL intravitreal; PRN re-treat guided by activity.

   • Purpose/mechanism: Same anti-VEGF effect, often used off-label due to cost.

   • Side effects: Same injection risks; compounded preparation quality matters.

4. Conbercept (anti-VEGF; regional availability)

   • Class: VEGF receptor fusion protein (similar concept to aflibercept).

   • Dose & timing: 0.5 mg intravitreal (varies by region/protocol); PRN retreatment.

   • Purpose/mechanism: Neutralizes VEGF family signals.

   • Side effects: As with other anti-VEGF injections.

5. Verteporfin Photodynamic Therapy (PDT) – drug + laser procedure

   • Class: Photosensitizer (drug) activated by 689-nm laser.

   • Dose & timing: Verteporfin 6 mg/m² IV over ~10 min; 15 min from infusion start, laser delivers standard energy to CNV. Retreatment considered if leakage persists.

   • Purpose: Shuts down CNV selectively (useful in some extrafoveal CNVMs or when anti-VEGF isn’t available/appropriate).

   • Mechanism: Light-activated verteporfin creates singlet oxygen that closes abnormal vessels.

   • Side effects: Photosensitivity (avoid bright light for 48 hours), back pain during infusion (rare), transient vision change.

6. Triamcinolone acetonide – intravitreal (adjunct in selected cases)

   • Class: Corticosteroid.

   • Dose & timing: 2–4 mg (0.05–0.1 mL) intravitreal; not first-line for myopic CNVM but sometimes used adjunctively (e.g., with PDT) in inflammatory components.

   • Purpose: Reduce inflammation and edema.

   • Mechanism: Dampens cytokines and vascular permeability.

   • Side effects: Eye pressure rise, cataract acceleration, infection risk.

7. Dexamethasone implant (0.7 mg) – intravitreal (selected scenarios)

   • Class: Sustained-release corticosteroid.

   • Dose & timing: 0.7 mg implant in the vitreous; effect ~3–4 months; not routine for myopic CNVM but may help resistant edema under specialist care.

   • Purpose/mechanism: Long-acting anti-inflammatory, reduces retinal swelling.

   • Side effects: IOP spikes, cataract progression, rare migration if posterior capsule compromised.

8. tPA (tissue plasminogen activator) – intravitreal for submacular hemorrhage

   • Class: Clot-dissolving enzyme.

   • Dose & timing: 25–50 µg/0.05 mL intravitreal with a gas bubble (SF6/C3F8) and face-down positioning; used case-by-case when a large bleed obscures the fovea.

   • Purpose: Displace/dissolve submacular blood to limit iron toxicity and scarring.

   • Mechanism: Breaks down fibrin in the hemorrhage.

   • Side effects: Retinal detachment, further bleeding, pressure changes—specialist procedure.

9. Ranibizumab biosimilars (regional products)

   • Class: Anti-VEGF biosimilar to ranibizumab.

   • Dose & timing: 0.5 mg/0.05 mL intravitreal; PRN retreatment.

   • Purpose/mechanism: Same as originator; cost-sensitive settings.

   • Side effects: As with anti-VEGF injections.

10. Pegaptanib (older anti-VEGF) – rarely used today

• Class: RNA aptamer targeting VEGF165.

• Dose & timing: 0.3 mg intravitreal every 6 weeks (historic).

• Purpose: Anti-VEGF effect; largely replaced by newer agents with broader VEGF binding and better outcomes.

• Side effects: As with intravitreal injections.

Important: Newer agents like brolucizumab or faricimab are widely used for other macular diseases; their role in myopic CNVM is not established and some carry specific inflammation/vasculitis risks. Your retina specialist will choose the safest, proven option for myopic CNVM.

---

Dietary, Molecular & Supportive Supplements

Supplements support general retinal health. They do not cure a CNVM and never replace injections. Discuss with your doctor, especially if pregnant, anticoagulated, or with kidney stones.

1. Lutein – 10 mg/day

   • Function: Antioxidant pigment for macula.

   • Mechanism: Filters blue light; quenches free radicals in photoreceptors.

2. Zeaxanthin – 2 mg/day

   • Function: Partners with lutein in the macula.

   • Mechanism: Stabilizes macular pigment; antioxidation.

3. Omega-3 (EPA+DHA) – ~1,000 mg/day total

   • Function: Retinal cell membrane health.

   • Mechanism: Anti-inflammatory lipid mediators; improves photoreceptor resilience.

4. Vitamin C – 500 mg/day

   • Function: Antioxidant recycling.

   • Mechanism: Scavenges oxidative stress in the retina.

5. Vitamin E – 400 IU/day

   • Function: Lipid membrane antioxidant.

   • Mechanism: Protects photoreceptor outer segments.

6. Zinc – 25–80 mg/day (as zinc oxide) + Copper 2 mg/day

   • Function: Enzyme cofactor; supports RPE.

   • Mechanism: Antioxidant enzymes (e.g., superoxide dismutase). Always pair with copper to avoid deficiency.

7. Astaxanthin – 4–12 mg/day

   • Function: Potent antioxidant carotenoid.

   • Mechanism: Reduces oxidative and inflammatory stress.

8. Saffron extract (crocin/crocetin) – 20–30 mg/day

   • Function: Visual function support.

   • Mechanism: Neuroprotective/antioxidant actions in macular tissue.

9. Bilberry anthocyanins – 100–320 mg/day

   • Function: Vascular/retinal support.

   • Mechanism: Strengthens capillaries; antioxidant effects.

10. Resveratrol – 150–500 mg/day

• Function: Anti-inflammatory/vascular health.

• Mechanism: Modulates oxidative pathways and endothelial function.

11. Curcumin (with piperine) – 500–1,000 mg/day

• Function: Anti-inflammatory support.

• Mechanism: NF-κB modulation; antioxidant.

12. Coenzyme Q10 – 100–200 mg/day

• Function: Mitochondrial energy support.

• Mechanism: Electron transport antioxidant in photoreceptors.

13. N-acetylcysteine – 600–1,200 mg/day

• Function: Glutathione booster.

• Mechanism: Replenishes intracellular antioxidant stores.

14. Taurine – 500–1,000 mg/day

• Function: Photoreceptor health.

• Mechanism: Osmoregulation; neuroprotection.

15. Multivitamin with trace minerals – per label

• Function: General nutritional backstop.

• Mechanism: Prevents deficiency that can worsen retinal stress.

Note for smokers: Avoid high-dose beta-carotene supplements due to increased lung-cancer risk. Choose lutein/zeaxanthin-based formulas instead.

---

Regenerative / Stem-Cell–Type” Therapies

Plain truth: There are no approved stem-cell or gene-therapy drugs for myopic CNVM as of today. The options below are investigational or surgical concepts. Do not pursue outside regulated clinical trials. Dosing is trial-specific and not established for clinical use in myopic CNVM.

1. AAV-based anti-VEGF gene therapy

   • Function: Eye makes its own anti-VEGF after a one-time procedure.

   • Mechanism: AAV vector delivers a gene encoding anti-VEGF protein to retinal cells.

   • Dosage: Investigational only (surgical/subretinal or suprachoroidal dosing in trials for other diseases).

   • Status: Not approved for myopic CNVM.

2. AAV-aflibercept gene therapy

   • Function: Long-term intraocular aflibercept expression.

   • Mechanism: AAV vector drives aflibercept production in the eye.

   • Dosage: Investigational only.

   • Status: Not approved for myopic CNVM.

3. iPSC-derived RPE patch transplantation

   • Function: Replace damaged retinal pigment epithelium.

   • Mechanism: Lab-grown RPE cells seeded on a scaffold placed under macula.

   • Dosage: Surgical cell number varies—trial only.

   • Status: Experimental; targets atrophy/scars rather than active CNV.

4. Embryonic stem-cell–derived RPE suspensions

   • Function: Restore supportive RPE layer.

   • Mechanism: Subretinal injection of RPE cells.

   • Dosage: Trial-defined; not standard.

   • Status: Experimental; long-term safety/benefit still studied.

5. Mesenchymal stem cell (MSC) approaches

   • Function: Theorized trophic/anti-inflammatory support.

   • Mechanism: Paracrine factors may aid retinal survival.

   • Dosage: Not established; serious safety concerns reported with unregulated clinics.

   • Status: Avoid outside trials; risk of severe complications.

6. Autologous RPE-choroid patch graft (surgical transplant)

   • Function: Move a healthy patch from outside the macula to the center.

   • Mechanism: Microsurgery replaces scarred area.

   • Dosage: Not a drug; complex surgery reserved for selected end-stage cases.

   • Status: Rare; variable outcomes; superseded by modern anti-VEGF in most cases.

---

Surgeries / Procedures

Surgery is not the first choice for active myopic CNVM. It is considered in special situations or for complications.

1. Thermal laser photocoagulation (for extrafoveal CNVM only)

   • Why: If the membrane lies away from the fovea, laser can seal it.

   • How: Focused laser burns close abnormal vessels. Risk: expansion of scar and recurrence.

2. Submacular surgery (CNV removal)

   • Why: Historic option before anti-VEGF; occasionally considered if massive bleed with clot.

   • How: Vitrectomy + delicate removal of the membrane. Risks: damage to photoreceptors, poor visual recovery.

3. Pars plana vitrectomy with tPA/gas for submacular hemorrhage

   • Why: Clear large foveal blood quickly to protect photoreceptors.

   • How: Remove vitreous, place tPA and gas bubble, face-down positioning to displace blood.

4. Macular translocation (rare, complex)

   • Why: Move the fovea onto healthier RPE.

   • How: Surgical rotation of the retina; high risk; seldom used now.

5. Posterior scleral reinforcement (for progressive staphyloma, selected)

   • Why: Support a thinning, bulging eye wall to slow structural worsening.

   • How: Surgical graft strengthens the posterior pole; aims to reduce ongoing stretch, not directly treat CNV.

---

Prevention strategies

1. Control myopia in childhood: Encourage ≥2 hours/day outdoors to slow myopia onset/progression.

2. Low-dose atropine (0.01–0.05%) in children under specialist care to slow myopia progression.

3. Orthokeratology or multifocal contact lenses (pediatric/teen myopia control programs).

4. Regular eye checks in high myopia: Annual (or as advised) visits with OCT when symptoms arise.

5. No smoking (and avoid second-hand smoke).

6. Manage blood pressure, diabetes, and lipids.

7. Protect from UV/bright light with quality sunglasses.

8. Avoid strong eye rubbing; treat allergies that cause itch.

9. Ergonomic near work: Good lighting, breaks (20-20-20 rule).

10. Know the symptoms: Any new waviness or central blur—seek urgent eye care.

---

When to see a doctor immediately

• Sudden wavy lines or a gray spot in the center of vision.

• New central blur that makes reading/phone use hard.

• A fresh patch of bleeding seen on photos or by a doctor.

• After an eye injection if you get severe pain, worsening vision, pus-like discharge, or light sensitivity—possible infection.

• If you’re pregnant or planning pregnancy and develop symptoms—ask how treatment timing may change.

• Any rapid change in one eye compared with the other.

---

What to eat (and what to avoid) for general retinal support

Eat more of:

1. Leafy greens (spinach, kale—lutein/zeaxanthin).

2. Colorful vegetables & fruits (berries, citrus—antioxidants).

3. Fatty fish twice weekly (salmon, sardine—omega-3).

4. Nuts & seeds (walnut, almond, flax—healthy fats).

5. Eggs (yolk has lutein/zeaxanthin).

Limit/avoid:

6. Smoking (not a food, but crucial).

7. Excess alcohol (affects nutrition and retina).

8. Trans fats & ultra-processed snacks (promote inflammation).

9. Very salty foods (blood pressure spikes).

10. Mega-doses of unproven supplements without medical advice.

---

Frequently Asked Questions

1. Is myopic CNVM the same as “wet AMD”?
   No. Both involve abnormal vessels, but myopic CNVM happens in high myopia from stretch/thinning, while wet AMD is age-related degeneration.

2. Will glasses or LASIK fix a CNVM?
   No. Glasses/LASIK correct focus, not leaky vessels. CNVM needs medical therapy (anti-VEGF).

3. How many injections will I need?
   Many myopic CNVMs improve with few injections (often 1–3 in year one), but you’ll be treated only when needed based on OCT and vision.

4. Do injections hurt?
   You get numbing drops; most people feel pressure, not sharp pain. The procedure is quick.

5. What are the risks of injections?
   The biggest concern is infection, which is rare. Call urgently if you have severe pain or worsening vision after an injection.

6. Can a CNVM go away on its own?
   Rarely, some become inactive, but waiting risks scarring. Early treatment protects vision.

7. Are all anti-VEGF drugs the same?
   They all block VEGF but differ in structure. Your doctor chooses based on evidence, access, and your response.

8. What if I’m pregnant?
   Tell your specialist. Timing and choices may change; sometimes treatment is deferred or adjusted after risk–benefit discussion with obstetrics.

9. Can diet and supplements replace injections?
   No. They support eye health but do not stop an active CNVM.

10. What about PDT (verteporfin)?
    It can help in selected cases or where anti-VEGF isn’t suitable. Your retina specialist will discuss pros/cons.

11. Will I be able to drive?
    Depends on vision in your better eye and local laws. Get a formal assessment if unsure.

12. Will CNVM come back?
    It can. That’s why home monitoring and regular checks matter even after vision improves.

13. Can I fly after an injection?
    Yes, flying is fine after anti-VEGF injections. (Special rules apply if you had a gas bubble for hemorrhage displacement—then no flying until cleared.)

14. Is bevacizumab safe if it’s “off-label”?
    It’s widely used off-label in eyes; quality compounding and sterile technique are essential.

15. What if treatment doesn’t help?
    Alternatives (switching anti-VEGF, PDT, managing hemorrhage) and vision-rehab can still improve daily function. Your team will individualize care.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 13, 2025.

PDF Document For This Disease Conditions References